Home › Funds › Venrock Adviser, LLC › VRDN
Venrock Adviser, LLC position in VRDN
VIRIDIAN THERAPEUTICS INC · Health Care
Venrock Adviser, LLC reported holding 3,257,917 shares of VRDN (VIRIDIAN THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$67.1M, representing 3.26% of its reported portfolio and ranking #9 among its reported holdings. Venrock Adviser, LLC has disclosed VRDN holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Venrock Adviser, LLC's VRDN position evolved
Venrock Adviser, LLC first disclosed a stake in VRDN in Q3 2023 at 3,082,622 shares (US$47.3M). The position peaked in Q4 2025 at 3,882,709 shares, worth US$120.8M. Across 13 filings, Venrock Adviser, LLC increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 10 time(s). The most recent filing (Q3 2026) shows 3,257,917 shares valued at US$67.1M. Notable position changes include a 26% increase in Q4 2023 (shares fell 20% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 3.08M | $47.29M | New |
| Q4 2023 | 3.88M | $84.56M | Add |
| Q1 2024 | 3.88M | $67.99M | Hold |
| Q2 2024 | 3.88M | $50.51M | Hold |
| Q3 2024 | 3.88M | $88.33M | Hold |
| Q4 2024 | 3.88M | $74.43M | Hold |
| Q1 2025 | 3.88M | $52.34M | Hold |
| Q2 2025 | 3.88M | $54.28M | Hold |
| Q3 2025 | 3.88M | $83.79M | Hold |
| Q4 2025 | 3.88M | $120.83M | Hold |
| Q1 2026 | 3.88M | $75.95M | Hold |
| Q2 2026 | 3.26M | $59.85M | Reduce |
| Q3 2026 | 3.26M | $67.08M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About VRDN and 13F data
VRDN (VIRIDIAN THERAPEUTICS INC) is a Health Care company. 40 other funds we track also report a position in VRDN — the largest reported positions include Paradigm Biocapital Advisors LP (US$227.1M), Bellevue Group AG (US$146.4M), Kynam Capital Management, LP (US$126.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding VRDN
- Paradigm Biocapital Advisors LP 12.41M sh · $227.08M · Q3 2026
- Bellevue Group AG 7.11M sh · $146.38M · Q3 2026
- Kynam Capital Management, LP 6.15M sh · $126.59M · Q3 2026
- Fairmount Funds Management LLC 5.09M sh · $104.82M · Q3 2026
- RTW INVESTMENTS, LP 4.98M sh · $102.03M · Q3 2026
- RA CAPITAL MANAGEMENT, L.P. 5.96M sh · $81.79M · Q3 2026
- Novo Holdings A/S 4.87M sh · $78.92M · Q3 2026
- Deep Track Capital, LP 3.83M sh · $64.34M · Q3 2026
- Atlas Venture Life Science Advisors, LLC 4.50M sh · $61.83M · Q3 2026
- Caligan Partners LP 3.08M sh · $57.34M · Q3 2026
- Context Capital Management, LLC 49.00M sh · $56.47M · Q3 2026
- Avoro Capital Advisors LLC 2.50M sh · $51.48M · Q3 2026
More on Venrock Adviser, LLC
FAQ
How long has Venrock Adviser, LLC held VRDN?
Venrock Adviser, LLC has disclosed VRDN holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is Venrock Adviser, LLC's current position in VRDN?
As of Q3 2026, Venrock Adviser, LLC holds 3.26M shares of VRDN (VIRIDIAN THERAPEUTICS INC), valued at $67.08M, representing 3.26% of its reported portfolio and ranking #9.
Has Venrock Adviser, LLC been buying or selling VRDN?
In the latest 13F filing (Q3 2026), Venrock Adviser, LLC held unchanged its position in VRDN. The position peaked in Q4 2025 at 3.88M shares.
Which other funds hold VRDN?
Other major institutional holders of VRDN include Paradigm Biocapital Advisors LP, Bellevue Group AG, Kynam Capital Management, LP, among 40 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.